Last reviewed · How we verify
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis
Approved treatments
- Mesnex · Baxter
Mesnex works by binding to and neutralizing acrolein, a toxic byproduct of chemotherapy that causes hemorrhagic cystitis.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of Chemotherapy-Induced Hemorrhagic Cystitis patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of Chemotherapy-Induced Hemorrhagic Cystitis treatment landscape brief
- Prevention of Chemotherapy-Induced Hemorrhagic Cystitis treatment updates RSS
Frequently asked questions about Prevention of Chemotherapy-Induced Hemorrhagic Cystitis
What drugs treat Prevention of Chemotherapy-Induced Hemorrhagic Cystitis?
Tracked treatments include Mesnex.
What is the treatment for Prevention of Chemotherapy-Induced Hemorrhagic Cystitis?
Standard treatment for Prevention of Chemotherapy-Induced Hemorrhagic Cystitis includes Mesnex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of Chemotherapy-Induced Hemorrhagic Cystitis patent cliff · Prevention of Chemotherapy-Induced Hemorrhagic Cystitis CI report
- Treatment: Mesnex · Baxter
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing